Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR045203)
National Institute of Neurological Disorders and Stroke (P01NS069539)
National Cancer Institute (T32CA009657)
National Institute of General Medical Sciences (T32GM007270 ()
National Human Genome Research Institute (T32HG00035)
Friends of FSH Research
Prinses Beatrix Spierfonds (W.OP14-01)
FSH Canada Foundation
Spieren voor Spieren
Received: 12 June 2017
Accepted: 14 August 2017
First Online: 4 September 2017
Ethics approval and consent to participate
: This study used pre-existing de-identified human cell lines from approved repositories and was determined not to be Human Subjects Research by the Fred Hutchinson Cancer Research Center Institutional Review Board and the Saint Louis University Institutional Biosafety Committee. Muscle samples were obtained from the Fields Center at the University of Rochester (ExternalRef removed), and subjects gave informed written consent prior to sample use.
: Not applicable.
: SJT and FMS have filed a provisional patent application titled “Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors,” but otherwise the authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.